Alveus Therapeutics

• Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

  Phase 2, Recruiting, 220 people, 24 Sept 2026

• Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

  Phase 1, Active, not recruiting, 180 people, 10 Feb 2026

Sources: clinicaltrials.gov

• Disrupted daily rhythms in light exposure and wrist temperature are associated with metabolic risk markers and obesity

  Consulting or advice, 10 Oct 2026

• Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis

  Consulting or advice, Fees or honoraria, Grants or research support, 7 Aug 2026

• Weight Loss Intervention Promoting an Adapted Mediterranean-Style Dietary Pattern: The DELISH Randomized Clinical Trial

  Fees or honoraria, 3 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov

• Molecular Risk Scores Enhance Type 2 Diabetes (T2D) Prediction beyond Hemoglobin A1c (HbA1c) and Body Mass Index (BMI) across Diverse Clinical Contexts

  ADA Scientific Sessions 2026 abstract, 7 Jun 2026

• Metabolic Response to Oral Semaglutide in Adults with Obesity—Weight Loss and Beyond: The GAROS Prospective Study

  ADA Scientific Sessions 2026 abstract, 6 Jun 2026